Company: Janssen

Clinical trial(s): Vivacity (Stage 2 complete) More information

NICE status: Awaiting development (topic selected 3/1/24)

MHRA status: Approved

  • Nipocalimab is a FcRn inhibitor, similar to how efgartigimod and rozanolixizumab work. It has already shown clinical effectiveness in treating four other autoantibody-driven diseases, such as rheumatoid arthritis.